Cambridge Investment Research Advisors’s AIM ImmunoTech AIM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-204	Closed	-$9K	–	3345
2023 Q1	$9K	Sell	204 -263	-56%	-$13.6K	﹤0.01%	3136
2022 Q4	$15K	Sell	467 -5	-1%	-$232	﹤0.01%	3067
2022 Q3	$27K	Buy	472 +5	+1%	+$350	﹤0.01%	2989
2022 Q2	$36K	Hold	467	–	–	﹤0.01%	2966
2022 Q1	$49K	Buy	+467	New	+$40.2K	﹤0.01%	3078
2021 Q4	–	Sell	-467	Closed	-$94K	–	3349
2021 Q3	$94K	Hold	467	–	–	﹤0.01%	2962
2021 Q2	$100K	Hold	467	–	–	﹤0.01%	2973
2021 Q1	$106K	Buy	467 +60	+15%	+$13.5K	﹤0.01%	2750
2020 Q4	$73K	Buy	407 +65	+19%	+$13K	﹤0.01%	2632
2020 Q3	$73K	Buy	+342	New	+$85.4K	﹤0.01%	2424

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cambridge Investment Research Advisors's AIM Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of AIM ImmunoTech (AIM) in Q2 2023, closing a stake of 204 shares — an estimated $9K sold.

Cambridge Investment Research Advisors first reported a position in AIM in Q3 2020 and held it in 10 quarters. The position peaked at $106K in Q1 2021. 30 funds tracked by Wall St. Rank hold AIM as of Q2 2023.

Cambridge Investment Research Advisors reported no remaining AIM ImmunoTech position as of Q2 2023 after selling out during the quarter.
Cambridge Investment Research Advisors sold 204 AIM ImmunoTech shares in Q2 2023, an estimated $9K.
Cambridge Investment Research Advisors first reported a position in AIM ImmunoTech in Q3 2020 and held it in 10 quarters.
Cambridge Investment Research Advisors's AIM ImmunoTech position peaked at $106K in Q1 2021.
30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.